PLK1 and breast carcinoma: Taken together, our results showed a substantial synergy of Plk1 inhibition and chemotherapy in basal-like and mesenchymal TNBC and warrant development of a clinical trial with onvansertib in combination with paclitaxel in a subset of breast cancer that currently carries a poor prognosis, and for which no targeted therapies exist.